06:47:43 Europe / Stockholm

Share price & Turnover

Share price change and turnover during the day of this press release

Subscription

Calendar

2026-02-20 Year-end Report 2025
2025-11-21 Quarterly Report 2025-Q3
2025-08-22 Quarterly Report 2025-Q2
2025-05-22 Quarterly Report 2025-Q1
2025-02-21 Year-end Report 2024
2024-11-21 Quarterly Report 2024-Q3
2024-08-22 Quarterly Report 2024-Q2
2024-05-24 Ex-date Ordinary Dividend ABLI 0.00 SEK
2024-05-23 Quarterly Report 2024-Q1
2024-05-23 Annual General meeting
2024-03-26 Extra General Meeting 2024
2024-02-23 Year-end Report 2023
2023-11-17 Quarterly Report 2023-Q3
2023-08-18 Quarterly Report 2023-Q2
2023-05-23 Quarterly Report 2023-Q1
2023-05-08 Ex-date Ordinary Dividend ABLI 0.00 SEK
2023-05-05 Annual General meeting
2023-03-08 Extra General Meeting 2022
2023-02-24 Year-end Report 2022
2022-11-22 Quarterly Report 2022-Q3
2022-08-19 Quarterly Report 2022-Q2
2022-05-31 Quarterly Report 2022-Q1
2022-05-20 Annual General meeting
2022-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2022-02-22 Year-end Report 2021
2021-11-19 Quarterly Report 2021-Q3
2021-08-19 Quarterly Report 2021-Q2
2021-05-21 Ex-date Ordinary Dividend ABLI 0.00 SEK
2021-05-20 Annual General meeting
2021-05-20 Quarterly Report 2021-Q1
2021-04-29 Extra General Meeting 2021
2021-02-19 Year-end Report 2020
2020-11-20 Quarterly Report 2020-Q3
2020-08-21 Quarterly Report 2020-Q2
2020-05-22 Ex-date Ordinary Dividend ABLI 0.00 SEK
2020-05-20 Quarterly Report 2020-Q1
2020-05-20 Annual General meeting
2020-03-17 Extra General Meeting 2020
2020-02-19 Year-end Report 2019
2019-11-20 Quarterly Report 2019-Q3
2019-08-21 Quarterly Report 2019-Q2
2019-05-21 Quarterly Report 2019-Q1
2019-04-26 Ex-date Ordinary Dividend ABLI 0.00 SEK
2019-04-25 Annual General meeting
2019-02-28 Year-end Report 2018
2019-01-17 Extra General Meeting 2018
2018-11-22 Quarterly Report 2018-Q3
2018-08-21 Quarterly Report 2018-Q2
2018-05-22 Quarterly Report 2018-Q1
2018-04-30 Ex-date Ordinary Dividend ABLI 0.00 SEK
2018-04-27 Annual General meeting
2018-02-20 Year-end Report 2017
2017-11-21 Quarterly Report 2017-Q3
2017-08-17 Quarterly Report 2017-Q2
2017-05-18 Quarterly Report 2017-Q1
2017-04-28 Ex-date Ordinary Dividend ABLI 0.00 SEK
2017-04-27 Annual General meeting
2017-02-21 Year-end Report 2016
2016-11-22 Quarterly Report 2016-Q3
2016-08-18 Quarterly Report 2016-Q2
2016-05-31 Quarterly Report 2016-Q1
2016-04-29 Ex-date Ordinary Dividend ABLI 0.00 SEK
2016-04-28 Annual General meeting
2016-03-31 Extra General Meeting 2016
2016-02-19 Year-end Report 2015
2015-11-18 Quarterly Report 2015-Q3
2015-08-19 Quarterly Report 2015-Q2
2015-05-20 Quarterly Report 2015-Q1
2015-03-31 Ex-date Ordinary Dividend ABLI 0.00 SEK
2015-03-30 Annual General meeting
2015-02-18 Year-end Report 2014
2014-11-19 Quarterly Report 2014-Q3
2014-08-20 Quarterly Report 2014-Q2
2014-05-12 Ex-date Ordinary Dividend ABLI 0.00 SEK
2014-05-09 Quarterly Report 2014-Q1
2014-05-09 Annual General meeting
2014-02-19 Year-end Report 2013
2014-01-21 Analyst Meeting 2014
2013-12-13 Extra General Meeting 2013
2013-11-20 Quarterly Report 2013-Q3
2013-08-23 Quarterly Report 2013-Q2
2013-05-24 Quarterly Report 2013-Q1
2013-03-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2013-03-08 Annual General meeting
2013-02-05 Year-end Report 2012
2012-10-15 Quarterly Report 2012-Q3
2012-08-21 Quarterly Report 2012-Q2
2012-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2012-06-08 Annual General meeting
2012-05-31 Quarterly Report 2012-Q1
2012-04-02 Extra General Meeting 2012
2012-02-21 Year-end Report 2011
2011-11-22 Quarterly Report 2011-Q3
2011-08-23 Quarterly Report 2011-Q2
2011-06-10 Annual General meeting
2011-05-17 Quarterly Report 2011-Q1
2011-02-22 Year-end Report 2010
2010-11-18 Quarterly Report 2010-Q3
2010-08-19 Quarterly Report 2010-Q2
2010-06-11 Ex-date Ordinary Dividend ABLI 0.00 SEK
2010-05-20 Quarterly Report 2010-Q1
2009-11-19 Quarterly Report 2009-Q3

Description

CountrySweden
ListSmall Cap Stockholm
SectorHealth care
IndustryBiotechnology
Abliva är ett läkemedelsbolag. Bolaget utvecklar läkemedel för behandling av primära mitokondriella sjukdomar. Dessa medfödda, sällsynta och ofta mycket svåra sjukdomar uppstår då cellens energiförsörjare, mitokondrierna, inte fungerar som de ska. Portföljen omfattar projekt i olika skeden och sträcker sig från tidig upptäcktsfas till klinisk fas. Bolaget gick tidigare under namnet NeuroVive Pharmaceutical.
2024-05-13 14:30:00

LUND, Sweden, May 13, 2024 (GLOBE NEWSWIRE) -- Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage company developing drugs for the treatment of rare and severe primary mitochondrial disease, today announced that it will host a virtual KOL event on Tuesday, May 21, 2024 at 10:00 AM ET / 4:00 PM CET, featuring Amel Karaa, MD (Massachusetts General Hospital), who will discuss the unmet medical need and current treatment landscape for patients with primary mitochondrial disease. There are currently no approved medicines for the systemic disease. To register, click here.

The event will focus on Abliva's lead program, KL1333, which has shown clinically meaningful, early signals of efficacy in mitochondrial disease patients. This novel therapeutic approach modulates the underlying pathophysiology in mitochondrial disease. KL1333 is currently being evaluated in the potentially registrational Phase 2 FALCON trial, with interim analysis expected mid-year 2024. KL1333 has Orphan Drug Designation (ODD) in both Europe and the U.S. and Fast Track designation in the U.S.

A live question and answer session will follow the formal presentation.

About Amel Karaa, MD

Amel Karaa, MD, is an internist and clinical geneticist by training and specializes in treating patients with complex medical conditions including primary mitochondrial diseases at the Massachusetts General Hospital in Boston. Dr. Karaa is a clinical researcher and a clinical trialist who has led and been involved in several national and international mitochondrial disease clinical trials at different stages of drug development.

Dr. Karaa is the 2013 United mitochondrial disease foundation (UMDF) fellow, a site investigator for the NIH North American Mitochondrial Disease Consortium (NAMDC), one of the Founders and Director of the Mitochondrial Care Network (MCN) overseeing mitochondrial disease expert centers in the US, Chair of the scientific/medical board of the UMDF, immediate past-president of the Mitochondrial Medicine society (MMS) and has more recently focused on developing a US wide clinical trial consortium for primary mitochondrial disorders; The Translational Research Advancing Therapy in Mitochondrial Diseases Consortium (TREAT MITO).

Abliva – Delivering mitochondrial health
Abliva discovers and develops medicines for the treatment of mitochondrial disease. This rare and often very severe disease occurs when the cell’s energy provider, the mitochondria, do not function properly. The company has prioritized two projects. KL1333, a powerful regulator of the essential co-enzymes NAD⁺ and NADH, has entered late-stage development. NV354, an energy replacement therapy, has completed preclinical development. Abliva, based in Lund, Sweden, is listed on Nasdaq Stockholm, Sweden (ticker: ABLI). For more information, please visit www.abliva.com. Subscribe to our news and follow us on LinkedIn and YouTube.

Investor Contact:
Joyce Allaire
Life Science Advisors
jallaire@lifesciadvisors.com
617.435.6602

Abliva AB Company Contact: 
Catharina Johansson
Deputy CEO, CFO & VP Investor Relations
ir@abliva.com
+46 (0)46-275 62 21

Medicon Village, SE-223 81 Lund, Sweden
info@abliva.com
Tel: +46 (0)46 275 62 20